- Allegra Orthopaedics (AMT) has secured a loan facility of up to $2 million to progress the company’s Bone Substitute Project
- The orthopaedic solutions provider is developing a composite biocompatible ceramic material known as Sr-HT-Gahnite
- The orthopaedic solutions provider is developing a composite biocompatible ceramic material known as Sr-HT-Gahnite
- Substantial shareholder Robinwood Investments will loan the funds, which may drawn down in tranches of $300,000 over a two-year term
- The loan enables AMT to pursue commercialisation, including gaining regulatory approvals from the U.S. Federal Drug Administration and Australia’s Therapeutic Goods Administration
- Allegra Orthopaedics shares last traded at 32 cents each
